

# SPEXIS AG CHF0.02

ISIN: CH0106213793 WKN: 10621379 Asset Class: Stock

## Company

2024/07/17 17:30:08

Price

0.07 CHF

Difference ▲ 1.45%(0.00)

## Contact Details

SPEXIS LTD.

Tel: +41-61-567-16-00

--

Fax: +41-61-567-16-01

Hegenheimermattweg 125

Web: <http://spexisbio.com>

4123 Allschwil

E-mail: [info@spexisbio.com](mailto:info@spexisbio.com)



## Company Profile

Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPPTA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	3,286,000		3,087,000		18,295,000	
<b>Common stock capital</b>		1,179,000		975,000		951,000
<b>Fixed assets</b>	13,491,000		26,863,000		31,601,000	
<b>Equity capital of a company</b>		2,287,000		19,401,000		30,223,000
<b>Cash and cash equivalents</b>	511,000		1,804,000		14,368,000	
<b>Accrued liabilities</b>		-		0		4,180,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		8,714,000		6,002,000		9,845,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		5,775,000		4,547,000		9,827,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		0
<b>Total assets</b>	16,777,000	16,777,000	29,951,000	29,951,000	49,897,000	49,897,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	-	28	50
<b>Equity ratio</b>	13.64%	64.78%	60.79%
<b>Debt-equity ratio</b>	633.36%	54.37%	64.51%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	0.00%	0.00%	0.00%

# SPEXIS AG CHF0.02

ISIN: CH0106213793 WKN: 10621379 Asset Class: Stock

## Income statement

	2023	2022	2021
Turnover	0	0	0
Net income	-19,618,000	-18,553,000	-11,861,000
EBIT	-19,312,796	-18,848,229	-10,671,294
Operating income before taxes	-19,618,000	-18,553,000	-11,861,000
Cash Flow	-	-12,118,000	-1,149,000
Net interest income	-762,000	-150,000	-1,442,000
Research and development expenses	12,232,000	9,768,000	875,000
Income taxes	-	0	0
Result from investments in subsidiaries, associates and other	-	0	0
Revenues per employee	-	0	0

## Board of Directors

Dan Hartman	Member of the administrative board
Dennis Ausiello	Member of the administrative board
Kuno Sommer	Member of the administrative board
Robert Clarke	Member of the administrative board
Bernard Bollag	Member of the administrative board

## Members of Management Board

Jeffrey D. Wager	Chairman of Managing Board
Jürgen Fröhlich	Member of Executive Committee